AI Engines For more Details: Perplexity Kagi Labs You
Smooth Muscle Relaxation: Deptropine citrate has smooth muscle relaxant properties, making it useful for conditions involving spasms or hyperactivity of smooth muscle. It can help relieve symptoms associated with gastrointestinal spasms, bronchospasm, and urinary tract spasms.
Gastrointestinal Disorders: Deptropine citrate may be prescribed for the treatment of gastrointestinal disorders characterized by spasms or hypermotility, such as irritable bowel syndrome (IBS) and functional dyspepsia. It helps reduce abdominal pain, cramping, and discomfort associated with these conditions.
Respiratory Conditions: Deptropine citrate may be used to relieve bronchospasm associated with conditions such as asthma, chronic bronchitis, or chronic obstructive pulmonary disease (COPD). By relaxing the smooth muscle in the airways, deptropine citrate helps improve airflow and relieve symptoms of wheezing and shortness of breath.
Urinary Disorders: Deptropine citrate may also be used to alleviate symptoms of urinary tract spasms, such as dysuria (painful urination), urinary urgency, and urinary frequency. It helps relax the smooth muscle of the bladder and urethra, reducing urinary tract spasms and discomfort.
Preoperative Medication: Deptropine citrate may be administered before surgery to reduce secretions in the respiratory and gastrointestinal tracts. By decreasing salivation and bronchial secretions, deptropine citrate helps maintain a clear airway during anesthesia and reduces the risk of aspiration.
Motion Sickness: Deptropine citrate may be used as part of the treatment regimen for motion sickness, particularly when associated with gastrointestinal symptoms such as nausea and vomiting. By blocking the action of acetylcholine in the vestibular system, deptropine citrate helps alleviate symptoms of motion-induced nausea and vertigo.
Dosage and Administration: Deptropine citrate is typically administered orally in the form of tablets or oral solutions. The dosage may vary depending on the individual's age, weight, medical condition, and response to treatment. It's important to follow the prescribed dosage and administration instructions provided by a healthcare provider.
Side Effects: Common side effects of deptropine citrate may include dry mouth, blurred vision, constipation, urinary retention, drowsiness, dizziness, and tachycardia. These side effects are usually mild and transient but may become more pronounced at higher doses or with prolonged use. Deptropine citrate may also cause anticholinergic side effects such as dry mouth, blurred vision, constipation, and urinary retention due to its anticholinergic properties.
Contraindications: Deptropine citrate is contraindicated in individuals with narrow-angle glaucoma, severe gastrointestinal obstruction, urinary retention, or myasthenia gravis. It should be used with caution in individuals with pre-existing cardiovascular disease, hypertension, or hyperthyroidism.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.2 | -0.2 | |
ADHD | 4.3 | 0.3 | 13.33 |
Age-Related Macular Degeneration and Glaucoma | 0.8 | 0.3 | 1.67 |
Allergic Rhinitis (Hay Fever) | 1.2 | 1 | 0.2 |
Allergies | 4 | 1.3 | 2.08 |
Allergy to milk products | 0.7 | 0.7 | 0 |
Alopecia (Hair Loss) | 1.7 | 1.7 | |
Alzheimer's disease | 2.2 | 4.5 | -1.05 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.7 | 0.7 | 4.29 |
Ankylosing spondylitis | 3.6 | 1.2 | 2 |
Anorexia Nervosa | 0.3 | 2 | -5.67 |
Antiphospholipid syndrome (APS) | 2.5 | 2.5 | |
Asthma | 0.3 | 1.4 | -3.67 |
Atherosclerosis | 0.7 | 2.6 | -2.71 |
Atrial fibrillation | 3 | 1.8 | 0.67 |
Autism | 7.2 | 9.1 | -0.26 |
Barrett esophagus cancer | 0.2 | 0.2 | 0 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 0.9 | 1 | -0.11 |
Brain Trauma | 0.7 | 0.9 | -0.29 |
Carcinoma | 2.7 | 2.3 | 0.17 |
Celiac Disease | 2.6 | 3.3 | -0.27 |
Cerebral Palsy | 0.9 | 1 | -0.11 |
Chronic Fatigue Syndrome | 3.4 | 6.2 | -0.82 |
Chronic Kidney Disease | 1.2 | 2.7 | -1.25 |
Chronic Lyme | 0.9 | -0.9 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.4 | 1.2 | 0.17 |
Chronic Urticaria (Hives) | 1 | 1.9 | -0.9 |
Coagulation / Micro clot triggering bacteria | 1.1 | 0.8 | 0.38 |
Colorectal Cancer | 3.7 | 1.2 | 2.08 |
Constipation | 2 | 0.6 | 2.33 |
Coronary artery disease | 1.2 | 0.6 | 1 |
COVID-19 | 8.5 | 13.7 | -0.61 |
Crohn's Disease | 6 | 6.5 | -0.08 |
cystic fibrosis | 0.5 | 1.1 | -1.2 |
deep vein thrombosis | 0.5 | 0.7 | -0.4 |
Depression | 8.7 | 7.5 | 0.16 |
Dermatomyositis | 0.2 | 0.2 | 0 |
Eczema | 0.6 | 1.7 | -1.83 |
Endometriosis | 2.3 | 1.2 | 0.92 |
Eosinophilic Esophagitis | 0 | 0.2 | 0 |
Epilepsy | 2.6 | 2.1 | 0.24 |
Fibromyalgia | 1.9 | 2.8 | -0.47 |
Functional constipation / chronic idiopathic constipation | 5.8 | 3.6 | 0.61 |
gallstone disease (gsd) | 1.1 | 0.7 | 0.57 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2 | 0.4 | 4 |
Generalized anxiety disorder | 0.9 | 1.5 | -0.67 |
giant cell arteritis | 0 | 0 | |
Glioblastoma | 0.2 | -0.2 | |
Gout | 0.2 | -0.2 | |
Graves' disease | 1.4 | 1.3 | 0.08 |
Halitosis | 0.6 | 0.2 | 2 |
Hashimoto's thyroiditis | 1.7 | 0.6 | 1.83 |
Hidradenitis Suppurativa | 0.3 | 0.2 | 0.5 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 3.5 | 0.7 | 4 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.4 | 0.25 |
hyperglycemia | 0.2 | 1.6 | -7 |
Hyperlipidemia (High Blood Fats) | 0.8 | 0.5 | 0.6 |
hypersomnia | 0.1 | -0.1 | |
hypertension (High Blood Pressure | 2 | 3.7 | -0.85 |
Hypothyroidism | 0.6 | -0.6 | |
Hypoxia | 0.9 | 0.9 | |
IgA nephropathy (IgAN) | 4.6 | -4.6 | |
Inflammatory Bowel Disease | 3.5 | 8.9 | -1.54 |
Insomnia | 0.7 | 1.4 | -1 |
Intelligence | 1.2 | 0.8 | 0.5 |
Intracranial aneurysms | 0.8 | 0.5 | 0.6 |
Irritable Bowel Syndrome | 3.7 | 4.9 | -0.32 |
Liver Cirrhosis | 3.4 | 2.3 | 0.48 |
Long COVID | 7.7 | 7.9 | -0.03 |
Low bone mineral density | 1.2 | -1.2 | |
Lung Cancer | 0.8 | 0.7 | 0.14 |
ME/CFS with IBS | 0.7 | 1.9 | -1.71 |
ME/CFS without IBS | 0.7 | 2.3 | -2.29 |
Menopause | 1.3 | 1.3 | |
Metabolic Syndrome | 6.6 | 7.1 | -0.08 |
Mood Disorders | 10.3 | 7.5 | 0.37 |
multiple chemical sensitivity [MCS] | 1 | 0.1 | 9 |
Multiple Sclerosis | 3.3 | 6 | -0.82 |
Multiple system atrophy (MSA) | 1.1 | 0.3 | 2.67 |
Neuropathy (all types) | 0.5 | 0.2 | 1.5 |
neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2 | 4.2 | -1.1 |
NonCeliac Gluten Sensitivity | 0.2 | -0.2 | |
Obesity | 6.5 | 3.6 | 0.81 |
obsessive-compulsive disorder | 6.1 | 3.6 | 0.69 |
Osteoarthritis | 1.3 | 1.3 | |
Osteoporosis | 0.8 | 0.8 | 0 |
pancreatic cancer | 0.7 | 0.7 | |
Parkinson's Disease | 2.4 | 4.2 | -0.75 |
Polycystic ovary syndrome | 2 | 1.4 | 0.43 |
Postural orthostatic tachycardia syndrome | 0 | 0.5 | 0 |
Premenstrual dysphoric disorder | 0.8 | 0.3 | 1.67 |
primary biliary cholangitis | 0.3 | 1.4 | -3.67 |
Psoriasis | 3.6 | 3.5 | 0.03 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.6 | 3.6 | 0.56 |
Rosacea | 0.3 | 0.5 | -0.67 |
Schizophrenia | 5.3 | 1.1 | 3.82 |
scoliosis | 0.2 | 1 | -4 |
Sjögren syndrome | 2.7 | 2.9 | -0.07 |
Sleep Apnea | 0.6 | 1.2 | -1 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | 0 |
Stress / posttraumatic stress disorder | 2.3 | 2.2 | 0.05 |
Systemic Lupus Erythematosus | 3.3 | 1.8 | 0.83 |
Tic Disorder | 1.5 | 1.7 | -0.13 |
Tourette syndrome | 0.2 | 0.4 | -1 |
Type 1 Diabetes | 3.4 | 2.4 | 0.42 |
Type 2 Diabetes | 7.6 | 7.1 | 0.07 |
Ulcerative colitis | 1.8 | 5.9 | -2.28 |
Unhealthy Ageing | 4.2 | 2.6 | 0.62 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.